Can targeted metabolomics predict depression recovery? Results from the CO-MED trial

Metabolomics is a developing and promising tool for exploring molecular pathways underlying symptoms of depression and predicting depression recovery. The Absolute IDQ ™ p180 kit was used to investigate whether plasma metabolites (sphingomyelins, lysophosphatidylcholines, phosphatidylcholines, and a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Translational psychiatry 2019-01, Vol.9 (1), p.11-11, Article 11
Hauptverfasser:	Czysz, Andrew H., South, Charles, Gadad, Bharathi S., Arning, Erland, Soyombo, Abigail, Bottiglieri, Teodoro, Trivedi, Madhukar H.
Format:	Artikel
Sprache:	eng
Schlagworte:	45/61 631/208/212/1728 631/378/340 692/53/2423 Adult Antidepressive Agents - therapeutic use Behavioral Sciences Biological Psychology Biomarkers - blood Depressive Disorder, Major - blood Depressive Disorder, Major - drug therapy Drug Therapy, Combination Female Humans Male Medicine Medicine & Public Health Mental depression Metabolites Metabolomics Middle Aged Neurosciences Pharmacotherapy Prognosis Psychiatric Status Rating Scales Psychiatry Regression Analysis Sociodemographics Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!